PINE BROOK, N.J., Feb. 13 /PRNewswire/ -- Elusys Therapeutics, Inc., a developer of targeted anti-infective therapeutics, today announced that it will be presenting new post exposure efficacy data on Anthim(TM), the Company’s anthrax therapeutic, at The 4th Annual American Society of Microbiology Biodefense Research Conference.
The conference brings together top scientists conducting critical research to defend against the growing threat of bioterrorism and decision makers shaping the future biodefense research agenda. The conference takes place February 15 - 18, 2006 at the Hyatt Regency Hotel in Washington, DC.
Leslie Casey, Ph.D., Executive Director, Preclinical Development & Immunology of Elusys Therapeutics, will make a presentation (#69D Posterboard 50) entitled, “Intramuscular Administration of Anthim(TM), a High-Affinity Anti-Protective Antigen MAb, Enhances Post-exposure Antibiotic Efficacy against Lethal B. anthracis Spore Challenge,” on Thursday, February 16, 2006 from 1:00 - 2:30 PM in the Columbia Ballroom.
About Anthim(TM)
Anthim is a high-affinity monoclonal antibody that targets the protective antigen (PA) component of anthrax, blocking the bacteria’s ability to form deadly toxins. Anthim is being developed under The Food and Drug Administration (FDA) Animal Rule, a regulatory process specifically designed for the development of medical countermeasures to bioterror threats. According to this rule, marketing approval of Anthim can be granted based on efficacy in relevant animal models with only Phase I safety trials required in humans. In Q4 2005, Elusys initiated a Phase I human safety study of Anthim and the drug has been granted Fast Track status by the FDA. The Company has initiated manufacturing scale-up to produce Anthim in commercial quantities in preparation for a potential US Government purchase for the Strategic National Stockpile.
For more information on Anthim(TM) please visit www.elusys.com/product_development_anthim.php
For more information on the ASM Biodefense Conference please visit www.asmbiodefense.org
About Elusys
Elusys is a privately-held biopharmaceutical company focused on the development of targeted anti-infective therapeutics. Current venture investors include Essex Woodlands Health Ventures LLC, Invesco Private Capital, Crescendo Ventures, EagleAdvisors, and the Legg Mason Emerald Fund. To date, the Company has been awarded $20M from the U.S. Government for the development of novel therapeutics to combat bioterror agents. For more information on Elusys please visit www.elusys.com.
Elusys Therapeutics, Inc.
CONTACT: Bryan Murphy of LaVoie Group, 781-596-0200 X-105, orbmurphy@lavoiegroup.com, for Elusys Therapeutics, Inc.
Web site: http://www.elusys.com//
